[English]  [Pусский]  [中文]  
ctt-journal > Pshonkin 2 et al. (Abstract)

Pshonkin 2 et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 9
doi: 10.3205/ctt-2010-No9-abstract56
© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "4th Raisa Gorbacheva Memorial Meeting on Hematopoietic Stem Cell Transplantation", Saint Petersburg, Russia, September 18–20, 2010

Contribute a comment


A nelarabine-induced remission in a patient with relapsed refractory T-ALL followed by allogeneic bone marrow transplantation (case report)

Aleksey V. Pshonkin, Edvard R. Biyachuev, Svetlana V. Minenko, Vadim V. Ptushkin

Federal Scientific Clinical Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia

Correspondence: Aleksey V. Pshonkin, Federal Scientific Clinical Center of Pediatric Hematology, Oncology and Immunology, 117/2, Leninsky pr., 117997, Moscow, Russia, E-mail: pshoni@spam is badrambler.ru


Patient Т, 20 years old, was admitted to the Department of Adolescent Hematology of our Center in January 2010 with relapsed T-ALL. In May 1999, the patient had been diagnosed with acute myelomonoblastic leukemia (М4 FAB) without eosinophilia. He was treated according to the AML-IPH-93 protocol; a remission being achieved after the induction course. Maintenance therapy was finished in December, 2000. However, in January 2005, T-ALL was diagnosed, immunotyping of the blast cells corresponding to pre-Т ALL with co-expression of myeloid antigen CD13. The patient received therapy in accordance with the ALL-BFM-90 protocol. After induction therapy, clinical remission was observed. Maintenance treatment was finished on 4/8/2006.

In January 2010 his clinical state worsened, and was accompanied by sub-febrile body temperature (up to 37.8). A routine blood analysis revealed high leukocytosis (72,000/mcl), containing 10% blast cells.

According to results of a bone marrow (BM) examination, blast cells were at 98%, immunotyping showed a pre-Т ALL phenotype, a сytogenetic study revealed a t(6;14) chromosome anomaly, and all specific cytochemical reactions proved to be negative. An HR1 block of chemotherapy was not efficient, since 56% blast cells were found in the control BM puncture. Due to an available related BM donor and the young age of the patient, we undertook an attempt for remission reinduction, employing 2 courses of nelarabine monotherapy at a dose of 2500 mg (a total dose of 7500 mg per course). Following the first course, 5% blasts were found in the BM, after the second round, 1.5 % remained. To maintain the remission state, an allogeneic hemopoietic stem cell transplantation was performed on the patient at the R. M. Gorbacheva Institute of Child Hematology and Transplantation in May, 2010. In conclusion, nelarabine monotherapy showed its efficiency for treatment in relapsed refractory T-ALL.

Keywords: nelarabine, allogeneic hematopoietic stem cell transplantation, refractory relapsed T-ALL


<-- Previous abstract        Contents        Next abstract -->

Contribute a comment